The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
First-line FOLFOX-4 plus panitumumab followed by 5-FU/LV plus panitumumab or single-agent panitumumab as maintenance therapy in patients (pts) with RAS wild-type, metastatic colorectal cancer (mCRC): The VALENTINO study.
 
Filippo Pietrantonio
No Relationships to Disclose
 
Marta Caporale
No Relationships to Disclose
 
Rosa Berenato
No Relationships to Disclose
 
Sara Lonardi
No Relationships to Disclose
 
Roberto Murialdo
No Relationships to Disclose
 
Emanuela Paterno
No Relationships to Disclose
 
Marco Tampellini
No Relationships to Disclose
 
Alessandro Stefano Bertolini
No Relationships to Disclose
 
Lorenza Rimassa
Consulting or Advisory Role - Lilly; Merck Serono
Travel, Accommodations, Expenses - ArQule
 
Chiara Cremolini
No Relationships to Disclose
 
Elisa Giommoni
No Relationships to Disclose
 
Gianluca Tomasello
No Relationships to Disclose
 
Raffaella Longarini
No Relationships to Disclose
 
Fausto Petrelli
No Relationships to Disclose
 
Alberto Zaniboni
No Relationships to Disclose
 
Enrico Cortesi
No Relationships to Disclose
 
Andrea Sartore Bianchi
No Relationships to Disclose
 
Ilaria Bossi
No Relationships to Disclose
 
Maria Di Bartolomeo
No Relationships to Disclose
 
Filippo G. De Braud
No Relationships to Disclose